{"title":"OCEANIC-AF和阿松德西安对心房颤动高危患者的疗效不如阿哌沙班:我们是否已经走到了 XIa 因子抑制剂的尽头?","authors":"Keith C. Ferdinand, Asaad Nakhle","doi":"10.1016/j.ahjo.2024.100464","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":72158,"journal":{"name":"American heart journal plus : cardiology research and practice","volume":"46 ","pages":"Article 100464"},"PeriodicalIF":1.3000,"publicationDate":"2024-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666602224001071/pdfft?md5=dcef97a58d558630a5736f14bf7ddda6&pid=1-s2.0-S2666602224001071-main.pdf","citationCount":"0","resultStr":"{\"title\":\"OCEANIC-AF and the inferior efficacy of asundexian compared to apixaban in patients at high risk with atrial fibrillation: Have we come to the end of the road for factor XIa inhibitors?\",\"authors\":\"Keith C. Ferdinand, Asaad Nakhle\",\"doi\":\"10.1016/j.ahjo.2024.100464\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":72158,\"journal\":{\"name\":\"American heart journal plus : cardiology research and practice\",\"volume\":\"46 \",\"pages\":\"Article 100464\"},\"PeriodicalIF\":1.3000,\"publicationDate\":\"2024-09-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2666602224001071/pdfft?md5=dcef97a58d558630a5736f14bf7ddda6&pid=1-s2.0-S2666602224001071-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"American heart journal plus : cardiology research and practice\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2666602224001071\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"American heart journal plus : cardiology research and practice","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666602224001071","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
OCEANIC-AF and the inferior efficacy of asundexian compared to apixaban in patients at high risk with atrial fibrillation: Have we come to the end of the road for factor XIa inhibitors?